Xtant Medical Holdings, Inc. (XTNT) is a Belgrade, Montana-based medical technology company that develops orthobiologics, spinal implant systems and surgical products for orthopedic and neurological surgeons. The stock traded at $0.21 on Monday, a decline of 22.22% from the previous session's close of $0.27. The direction was decisively lower. The immediate reason cited by the market was the company's third-quarter 2026 financial report, which paired a steep year-over-year revenue decline and a swing to a net loss with the withdrawal of full-year guidance and the launch of a board-led strategic review.
Third-quarter revenue of $24.3 million fell from $33.3 million in the prior-year period. Roughly $5.4 million of the gap came from divested non-core assets, including the Coflex/CoFix line and the international hardware business, and about $5.5 million reflected the absence of wound care licensing revenue that carried unusually high margins. Sequentially, revenue rose 5% from $23.0 million, and biologics sales of $19.3 million climbed 13% year over year, including $2.2 million from HEMOBLAST Bellows.
Profitability deteriorated sharply. Gross margin contracted to 56.3% from 66.1%, gross profit fell to $13.7 million from $22.0 million, and the company swung to a net loss of $3.6 million, or $0.03 per share, from net income of $1.3 million, or $0.01 per diluted share. Adjusted EBITDA shifted to a loss of $1.5 million from positive $4.5 million a year earlier and stands at a $5.7 million loss on a nine-month basis. Management said it no longer expects to achieve previously issued full-year 2026 guidance and will not publish revised guidance while the review is under way — a decision that removes the earnings anchor investors use to value the equity.
The board disclosed it has been conducting a comprehensive review of strategic, operational and financial alternatives, including operational improvements, capital structure changes, partnerships, restructurings, acquisitions and dispositions. No timetable has been set, and the company cautioned that the process may not result in any transaction. Chairman Stavros Vizirgianakis called the quarter's performance "unacceptable" and noted it was the second straight period in which results missed guidance. The combination of an open-ended process and the cancellation of the quarterly conference call left investors without management commentary to offset the numbers.
Xtant ended the quarter with $7.8 million in cash and cash equivalents, down from $17.1 million at the start of the year, against $22.0 million of total indebtedness and just $2.1 million of availability under its revolving credit facility. Management said current liquidity should fund operations for at least twelve months, but with credit agreements carrying minimum liquidity and net revenue covenants, the margin for error is narrow. For a company with a market capitalization of roughly $25 million, that leverage profile magnifies the impact of any revenue shortfall.
The decline was company-specific rather than a sector-wide repricing, with no peer or industry catalyst accounting for a move of this size. Volume in the opening hour ran above the stock's recent daily averages, consistent with a news-driven repricing rather than a single block trade, although the order book in a sub-$1 microcap remains thin enough to amplify percentage moves. Technically, the shares had already been sliding since late September, when they traded near $0.375, and Monday's drop carried the stock to its lowest level of the past several months, breaking below the $0.26–$0.27 floor that had held through October and early November. The stock sits well beneath any meaningful moving average, a configuration that tends to invite further selling from momentum-sensitive holders.
The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 71 out of 100.
The verified news was substantial relative to the company's size: a loss-making quarter, a second consecutive guidance miss, formal withdrawal of the full-year outlook, and an open-ended strategic review at a company valued near $25 million. The move was also unusually large. It was roughly 6.6 times the stock's average absolute daily change of about 3.4% over the past 60 sessions, and only one of those sessions produced a comparable decline. Strong news and a rare move combine into the high score.
Attention turns to the Form 10-Q for the September quarter, expected around the filing date of the earnings release, which will give investors the first detailed look at cash burn and covenant compliance since the guidance withdrawal. The next scheduled financial update would be fourth-quarter and full-year 2026 results in early 2027, though the absence of guidance means expectations are now unanchored. Analyst coverage is sparse, so revisions may be slow to arrive. The strategic review is the dominant swing factor: any announced transaction, divestiture or capital raise would reset the investment case, while indefinite silence keeps uncertainty elevated. Risks include continued erosion in the core biologics trajectory, tighter revolver availability, potential covenant pressure, and the possibility that the review concludes without an actionable outcome.
Tickeron maintains a curated Trending AI Robots page that surfaces the automated strategies performing best under current market conditions. The platform hosts hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers earn a place in this featured section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as conditions change. Reviewing the current leaders can help traders see how systematic approaches are positioning across equities like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XTNT's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for XTNT just turned positive on November 04, 2026. Looking at past instances where XTNT's MACD turned positive, the stock continued to rise in 43 of 48 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTNT advanced for three days, in 195 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
XTNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XTNT as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for XTNT entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.015) is normal, around the industry mean (4.142). P/E Ratio (-3.618) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.426) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. XTNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of surgical products
Industry MedicalNursingServices